MedinCell S.A (MDCLF PINK) stock market data APIs
$34.2663
0(0%)
as of October 8, 2026
Try our APIs with
free plan!
MedinCell S.A Financial Data Overview
Price chart is built with
Anychart
MedinCell S.A. engages in the research and development of biodegradable polymer-based processes for the controlled and prolonged delivery of active pharmaceutical ingredients into the human body and animals in France. The company offers UZEDY, a subcutaneous risperidone for the treatment of schizophrenia. It also develops mdc-TJK, a subcutaneous injection, which is in NDA stage for the treatment of schizophrenia; and mdc-CWM, a sustained-release formulation of celecoxib, which is in Phase III clinical trial for the treatment and reduction of post-operative pain and inflammation. In addition, the company engages in the development of products in preclinical stage, including mdc-WWM for contraception; mdc-STM for the treatment of malaria; and mdc-AbbVie-1. It has strategic collaborations with TEVA, AIC, ABBVIE, Unitaid, and Gates Foundation. The company was incorporated in 2003 and is headquartered in Jacou, France.
Prev. Close
34.2663
Open
34.2663
High
34.2663
Low
34.2663
52 wk Range
6.976-34.39
Market Cap
1 235 M
Shares Outstanding
35 922 K
Revenue
24 277 K
EPS
-0.2722
Beta
0.917
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get MedinCell S.A data using free add-ons & libraries
Get MedinCell S.A Fundamental Data
MedinCell S.A Fundamental data includes:
- Net Revenue: 24 277 K
- EBITDA: -20 038 000
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2021-09-30
- EPS/Forecast: 0
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
MedinCell S.A News
New
Teva, Medincell granted FDA review for long-acting antipsychotic
[US Food and Drug Administration (FDA)] Teva Pharmaceutical (TEVA [https://seekingalpha.com/symbol/TEVA]) and its European partner Medincell (MDCLF [https://seekingalpha.com/symbol/MDCLF]) announced ...
Medincell - UZEDY®: Net Sales Increased from $117M in 2024 to $191M in 2025 (+63%)
OLANZAPINE LAI: EU Submission Expected in Q2 2026 MONTPELLIER, France, January 28, 2026--(BUSINESS WIRE)--Regulatory News: Medincell’s (Paris:MEDCL) partner, Teva Pharmaceuticals, today shared the...
3 European Growth Companies With Up To 21% Insider Ownership
As European markets navigate renewed trade and geopolitical uncertainties, with major indices like the STOXX Europe 600 Index ending lower, investors are increasingly focusing on insider ownership as ...
European Growth Stocks With High Insider Ownership For December 2025
As the European market edges closer to record highs, driven by positive sentiment around earnings and economic prospects for the coming year, investors are increasingly focusing on growth stocks with ...
Get MedinCell S.A fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.